Table of Contents Author Guidelines Submit a Manuscript
Malaria Research and Treatment
Volume 2015 (2015), Article ID 579864, 8 pages
http://dx.doi.org/10.1155/2015/579864
Clinical Study

Sustained Release Formulation of Primaquine for Prevention of Relapse of Plasmodium vivax Malaria: A Randomized, Double-Blind, Comparative, Multicentric Study

1Medical Affairs and Clinical Research, Ipca Laboratories Limited, Mumbai 400067, India
2Clinical Research & Development, Ipca Laboratories Limited, Mumbai 400067, India
3Department of Clinical Pharmacology, Seth G. S. Medical College & K. E. M. Hospital, Mumbai 400012, India
4Department of Medicine, Grant Medical College & Sir J. J. Group of Hospitals, Mumbai 400008, India
5Department of Medicine, Padmashree Dr. D. Y. Patil Medical College, Pimpri, Pune 411018, India
6Department of Medicine, B. Y. L. Nair Charitable Hospital & T. N. Medical College, Mumbai 400008, India
7Department of Medicine, IPGMER and SSKM College & Hospital, Kolkata 700020, India
8Department of Medicine, R. G. Kar Medical College & Hospital, 1 Kshudiram Bose Sarani, Kolkata 700004, India
9Department of Medicine, Dr. S. N. Medical College, Jodhpur 342003, India
10Kothari Medical and Research Institute, Bikaner 334004, India
11Kasturba Hospital for Infectious Diseases, Mumbai 400011, India

Received 4 July 2015; Accepted 3 August 2015

Academic Editor: Polrat Wilairatana

Copyright © 2015 Anil Pareek et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Arévalo-Herrera, C. Chitnis, and S. Herrera, “Current status of Plasmodium vivax vaccine,” Human Vaccines, vol. 6, pp. 124–132, 2010. View at Google Scholar · View at Scopus
  2. A. P. Dash, N. Valecha, A. R. Anvikar, and A. Kumar, “Malaria in India: challenges and opportunities,” Journal of Biosciences, vol. 33, no. 4, pp. 583–592, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. Y.-K. Goo, E.-J. Seo, Y.-K. Choi et al., “First characterization of Plasmodium vivax liver stage antigen (PvLSA) using synthetic peptides,” Parasites & Vectors, vol. 7, no. 1, article 64, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. World Health Organization, Guidelines for the Treatment of Malaria, World Health Organization, Geneva, Switzerland, 2nd edition, 2010.
  5. Prescribing information, Pr Primaquine. Primaquine phosphate tablets USP 26.3 mg primaquine phosphate (equivalent to 15 mg primaquine base), Sanofi-aventis Canada, 2014.
  6. D. Fernando, C. Rodrigo, and S. Rajapakse, “Primaquine in vivax malaria: an update and review on management issues,” Malaria Journal, vol. 10, article 351, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. D. S. Walsh, S. Looareesuwan, P. Wilairatana et al., “Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand,” The Journal of Infectious Diseases, vol. 180, no. 4, pp. 1282–1287, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Takeuchi, S. Lawpoolsri, M. Imwong et al., “Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border,” Malaria Journal, vol. 9, no. 1, article 308, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Leslie, M. A. Rab, H. Ahmadzai et al., “Compliance with 14-day primaquine therapy for radical cure of vivax malaria—a randomized placebo-controlled trial comparing unsupervised with supervised treatment,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 98, no. 3, pp. 168–173, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Kondrashin, A. M. Baranova, E. A. Ashley, J. Recht, N. J. White, and V. P. Sergiev, “Mass primaquine treatment to eliminate vivax malaria: lessons from the past,” Malaria Journal, vol. 13, article 51, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. A. R. Anvikar, U. Arora, G. S. Sonal et al., “Antimalarial drug policy in India: past, present, and future,” Indian Journal of Medical Research, vol. 139, pp. 205–215, 2014. View at Google Scholar · View at Scopus
  12. D. Bunnag, J. Karbwang, A. Thanavibul et al., “High dose of primaquine in primaquine resistant vivax malaria,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 88, no. 2, pp. 218–219, 1994. View at Publisher · View at Google Scholar · View at Scopus
  13. J. K. Baird and K. H. Rieckmann, “Can primaquine therapy for vivax malaria be improved?” Trends in Parasitology, vol. 19, no. 3, pp. 115–120, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. U. Silachamroon, S. Krudsood, S. Treeprasertsuk et al., “Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand,” The American Journal of Tropical Medicine and Hygiene, vol. 69, no. 1, pp. 14–18, 2003. View at Google Scholar · View at Scopus
  15. N. A. Kshirsagar, “Malaria: antimalarial resistance and policy ramifications and challenges,” Journal of Postgraduate Medicine, vol. 52, no. 4, pp. 291–293, 2006. View at Google Scholar · View at Scopus
  16. L. H. Schmidt, R. Fradkin, D. Vaughan, and J. Rasco, “Radical cure of infections with Plasmodium cynomolgi: a function of total 8-aminoquinoline dose,” The American Journal of Tropical Medicine and Hygiene, vol. 26, no. 6, pp. 1116–1128, 1977. View at Google Scholar · View at Scopus